Hematology & Blood & Marrow Transplant (BMT)

Hematology, Blood & Marrow Transplant, and Cellular Therapy (HBC) Program

(415) 353-2421

The UCSF Hematology, Blood and Marrow Transplant, and Cellular Therapy (HBC) Program is dedicated to providing the most advanced treatment options with care and compassion. Our acclaimed program draws patients from throughout the United States and abroad who seek exceptional and innovative treatment from providers specializing in blood disorders and cancers.

UCSF is also home to a robust research program for hematology, BMT and CAR T-cells. Patients may have the option to participate in clinical trials, including studies of cutting-edge immunotherapy treatments, such as tumor vaccines and CAR T-cell therapy.

CAR T-Cell Therapy

Our clinical and research teams are internationally renowned for their pioneering work in cell-based immunotherapy for cancer. UCSF gained a unique place in the history of cancer immunotherapy when UCSF-affiliated physicians and scientists initially developed and tested the first FDA-approved checkpoint inhibitor ipilimumab (Yervoy) in patients in 2011. We continue to work at the forefront of the field and are actively involved in CAR (chimeric antigen receptor) T-cell treatment and research.

FDA-approved CAR T-cell therapy uses a patient’s immune system to fight certain cancers. The therapy is a one-time treatment used when those cancers have resisted all other therapeutic options or have recurred more than once

CAR T-cell therapy has resulted in long-term remissions for many patients with B-cell non-Hodgkin’s lymphoma, B-cell acute lymphoblastic leukemia, and mantle cell lymphoma. Research is ongoing to evaluate it as a treatment for other blood cancers, including multiple myeloma, and solid tumors of the breast, prostate, brain, lungs and other organs.

Comprehensive Cancer Center

As part of the UCSF Helen Diller Family Comprehensive Cancer Center, we offer our cancer patients access to many services, including support groups, exercise and mindfulness classes, psychosocial support, symptom management and much more. 

Parker Institute for Cancer Immunotherapy

Our program is a member of the Parker Institute for Cancer Immunotherapy, a consortium made up of 10 of the world’s leading cancer centers. Its mission is to turn cancer into a curable disease by accelerating the development of breakthrough immune therapies.

Our locations

Expand Map

    Conditions we treat

    Patient education

    Hematology and BMT Resource Guide

    This hematology and bone marrow transplant (BMT) resource guide provides information about diseases and treatments, employment, insurance and more.

    Autologous Transplant Guide

    Having a blood and marrow transplant (BMT) is a difficult experience. Read this guide to help prepare you and your family and book an appointment today.

    Matched Unrelated Donor Transplantation

    Bone marrow transplantation can be performed using one's own bone marrow or by using another person's bone marrow. Learn more here.

    Our team

    Decorative Caduceus

    A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (C...

    The primary objective of this access and distribution protocol is to examine the incidence of neutrophil recovery of ≥500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not FDA licensed.

    Recruiting

    Decorative Caduceus

    Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disea...

    The Kaplan-Meier method will be used to estimate OS, including medians and confidence intervals. Comparison of OS between treatment arms will be conducted using a one-sided log-rank test stratified with mantle cell lymphoma Intern...

    Recruiting

    Decorative Caduceus

    Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refrac...

    Treatment-related Adverse events resulting in a DLT will be summarized by maximum toxicity grade for each dose level of isatuximab.

    Recruiting

    Decorative Caduceus

    Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving ...

    Timely engraftment is defined as a persistent an absolute neutrophil count (ANC) of at least 500 cells/mm3 and a platelet count of at least 20,000 cells/mm3 for at least 3 days

    Recruiting

    Decorative Caduceus

    Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymph...

    Defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients). The number and severity of all adverse events will be tabulated and...

    Recruiting

    Decorative Caduceus

    Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

    The feasibility of completing molecular, genetic, immunophenotypic, and biochemical testing for assignment of therapy will be assessed based on the proportion of patients for whom testing is completed within 7 days of the registra...

    Recruiting

    Decorative Caduceus

    Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin...

    Subjects treated with conforming product who received the target doses of anti-CD19 CAR-T infusion will be included in the analysis. Proportion of participants with treatment-emergent adverse events of CAR-T in B-cell NHL, as grad...

    Recruiting

    Decorative Caduceus

    Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorub...

    There will be no formal statistical testing for the dose-finding portion of the study.

    Recruiting

    Decorative Caduceus

    CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

    MTD is defined as the cohort of participants one cohort below the cohort that develop dose-limiting toxicity (DLT) in at least 2 participants.

    Recruiting

    Decorative Caduceus

    Study of APVO436 in Patients With AML or MDS

    Identify the maximum tolerated dose in dose-escalation (Phase 1) by assessment of dose-limiting toxicities

    Recruiting

    Rankings & achievements

    • usnews-neurology

      Among the top hospitals in the nation

    • Best in Northern California for cancer care (tie)

    • 220-2x

      blood and marrow transplants performed each year

    • 1986-2x

      Founded in 1986

    Accreditations & memberships

    • National Cancer Institute

      The National Cancer Institute has designated UCSF a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.

      Learn more

    • Commission on Cancer

      UCSF's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.

      Learn more

    • National Comprehensive Cancer Network

      UCSF is a founding member of the National Comprehensive Cancer Network, an alliance of the world’s top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.

      Learn more

    • FACT Accreditation

      Our Hematology, BMT and Cellular Therapy Program is accredited by the Foundation for Accreditation of Cellular Therapy (FACT). FACT-accredited programs follow specific high-quality medical and laboratory processes when providing cellular therapies such as BMT.

      Learn more

    Support services

    ""
    Patient Resource

    Case Management & Social Work

    Connect with a team that can help you find resources, solve problems and advocate for you during treatment at UCSF.

    Patient Resource

    Kôz Hospitality House

    Kôz Hospitality House provides comfortable, reasonably priced accommodations near our Parnassus campus for UCSF patients during their treatment.

    Class

    Mindfulness-Based Stress Reduction Class

    This eight-week class teaches mindfulness practices that can reduce stress and improve your overall health, such as meditation and body awareness.

    Patient Resource

    Patient Relations

    We welcome feedback about your experience at UCSF Health. Find out how to contact us with comments, questions or concerns.

    Patient Resource

    Spiritual Care Services

    Chaplains representing many faiths are available around the clock to provide support, comfort and counsel to patients, families and caregivers.

    Preparing for your appointment

    What to Bring

    • Photo I.D.
    • Health insurance card
    • Insurance authorization, if required
    • Doctor's referral, if required
    • Recent test results related to your condition
    • List of your medications, including dosages, plus any you're allergic to
    • List of questions you may have
    • Device or paper for taking notes

    International Services

    If you live outside the United States and are coming to UCSF for medical treatment, our patient liaisons can help coordinate all aspects of your visit.

    Learn more

    Interpreting Services

    UCSF offers interpreters in various languages, including American Sign Language (ASL), as well as services for deaf, hard-of-hearing and visually impaired patients.

    Learn more

    Hospital Stays

    Checking into the hospital? Find helpful information by clicking on the relevant “Your Hospital Stay” booklet: Mission Bay, Parnassus or Mount
    Zion.

    Learn more

    Your Doctor Visit

    See our top 10 tips for making your UCSF doctor’s appointment as stress-free and productive as possible.

    Learn more

    Guides and forms

    Related clinics

    Hemophilia Treatment Center

    400 Parnassus Ave., 4th Floor
    San Francisco, CA 94143

    (415) 476-4170
    M-F, 8 a.m. - 5 p.m.

    Cancer Immunotherapy Clinic

    Bakar Precision Cancer Medicine Building

    1825 Fourth St., Fifth Floor
    San Francisco, CA 94158

    (415) 353-2421

    Cancer Immunotherapy Toxicity Evaluation (CITE) Program

    Bakar Precision Cancer Medicine Building

    1825 Fourth St.
    San Francisco, CA 94158

    (415) 514-5860
    M-F, 8 a.m. - 5 p.m.

    Cancer Symptom Management

    Bakar Precision Cancer Medicine Building

    1825 Fourth St.
    San Francisco, CA 94158

    (415) 885-7671

    Cancer Center Redwood City

    2900 Whipple Ave., Suite 130
    Redwood City, CA 94062

    (650) 341-9131

    Cancer Center San Mateo

    218 DeAnza Blvd.
    San Mateo, CA 94402

    (650) 341-9131
    M-F, 9 a.m. - 6 p.m.

    Psycho-Oncology

    Bakar Precision Cancer Medicine Building

    1825 Fourth St.
    San Francisco, CA 94158

    (415) 353-7019

    UCSF-John Muir Health Cancer Center in Berkeley

    Berkeley Outpatient Center

    3100 San Pablo Ave., Suite 280
    Berkeley, CA 94702

    (510) 420-8000
    M-F, 8 a.m. - 6 p.m.

    Our research initiatives

    • UCSF-Helen-Diller-Family-Comprehensive-Cancer-Center-Research-2x

      UCSF Helen Diller Family Comprehensive Cancer Center Research

      UCSF is home to a range of research initiatives aimed at improving outcomes for cancer patients everywhere. This includes research on topics such as immunotherapy, BRCA mutations and molecular diagnostic testing.

      Learn more

    Do you need pediatric care?

    UCSF Benioff Children's Hospitals
    UCSF Benioff Children's Hospitals

    Can't find what you're looking for?

    UCSF Help Center

    (888) 689-8273
    [email protected]

    Share